Advertisement
ABBV vs PFE
Which Stock Would AI Choose? AbbVie (ABBV) vs. Pfizer (PFE) Stock Comparison
Key Takeaways
- AbbVie (ABBV) boasts a stronger growth trajectory post-patent cliff, with immunology drugs like Skyrizi and Rinvoq driving revenue, while Pfizer (PFE) relies on a broader portfolio amid declining COVID-related sales.
- PFE offers a higher dividend yield of approximately 6.4% compared to ABBV's 3.5%, appealing to income-focused investors.
- In recent market activity, ABBV has faced downward pressure, declining around 7% over the past month, while PFE dipped about 3%, showing relative stability.
- Analyst price targets indicate greater upside potential for ABBV at around $249 (25% from current levels) versus PFE's $29 (7% upside).
- Both stocks exhibit low beta values (under 0.4), signaling defensive qualities in volatile markets, but ABBV's forward P/E (price-to-earnings ratio) of 14 reflects higher growth expectations than PFE's 9.2.
- Upcoming quarterly earnings—ABBV on April 29 and PFE on May 5—could shift sentiment based on pipeline updates.
Introduction
AbbVie (ABBV) and Pfizer (PFE) represent cornerstone players in the pharmaceutical sector, both navigating patent expirations and pipeline innovations amid evolving market dynamics. This ABBV vs. PFE stock comparison examines their relative performance, business models, and positioning. Traders seeking momentum plays and long-term investors prioritizing dividends or growth will find value in understanding contrasts in valuation, sentiment, and catalysts. With both exhibiting resilience year-to-date, recent volatility underscores trade-offs in risk and reward within healthcare's defensive landscape.
ABBV Overview and Recent Performance
AbbVie (ABBV), spun off from Abbott Laboratories in 2013, specializes in immunology, oncology, and neuroscience, with flagship products Skyrizi and Rinvoq offsetting Humira's patent cliff. Trading around $199 recently, the stock has shown year-to-date gains of about 12% but faced pressure in recent weeks, declining roughly 7% over the past month amid broader market activity. A key setback was the FDA's Complete Response Letter (CRL) for its trenibotulinumtoxinE wrinkle treatment due to manufacturing issues, tempering enthusiasm. However, manufacturing investments, like a $1.4 billion North Carolina campus, and Q1 earnings anticipation (April 29) support sentiment. Low beta (0.36) and a 3.5% dividend yield reinforce its stability.
PFE Overview and Recent Performance
Pfizer (PFE), a diversified biopharma giant, spans vaccines, oncology, and rare diseases, with Comirnaty and Paxlovid sales waning post-COVID. At approximately $27, shares have delivered year-to-date returns near 10% and 17% over the past year, with a milder 3% monthly dip in recent trading. Positive developments include a collaboration with Bristol Myers Squibb for discounted Eliquis pricing and a reaffirmed quarterly dividend of $0.43 (6.4% yield). Mixed pipeline news—strong prostate cancer data offset by Lyme vaccine shortfalls—has influenced modest momentum. With beta at 0.39 and Q1 earnings due May 5, PFE appeals for income amid value positioning.
Trending AI Robots
Tickeron's Trending AI Robots page curates the top 25 performers from 351 AI trading bots that collectively trade thousands of tickers across stocks, ETFs, and crypto. Selected by AI for excelling in volatile conditions, these bots showcase impressive stats: annualized returns ranging from 15% to over 127%, win rates of 55-88%, and strategies spanning 5-minute to 60-minute timeframes. Examples include semiconductor-focused bots with 90%+ returns on tickers like SOXL and LRCX, and multi-ticker portfolios in energy or gold miners averaging 50-100% gains. Diverse styles—from trend-following to micro-cap signals—adapt to current markets. Explore these high-performing options to enhance your trading edge.
Head-to-Head Comparison
In business models, ABBV emphasizes high-margin immunology (revenue ~$61B TTM), contrasting PFE's broader exposure (~$63B TTM) including vaccines. Growth drivers favor ABBV's post-Humira pipeline, while PFE battles commoditized COVID products. Recent momentum tilts to PFE's steadier short-term chart, but ABBV leads longer-term returns. Risk factors include regulatory hurdles for both—ABBV's FDA CRLs, PFE's trial misses—yet PFE's higher debt/equity (78%) adds leverage risk. Sector-wise, both benefit from healthcare tailwinds, but sentiment leans ABBV for growth at a premium valuation versus PFE's value play.
Tickeron AI Verdict
Tickeron's AI models currently favor ABBV over PFE, citing superior trend consistency, pipeline catalysts, and relative market positioning. With improving EPS estimates and higher analyst upside, ABBV edges out despite short-term volatility, though PFE's yield provides a compelling counterbalance in uncertain conditions.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABBV is a Hold and PFE is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ABBV’s FA Score shows that 4 FA rating(s) are green whilePFE’s FA Score has 2 green FA rating(s).
- ABBV’s FA Score: 4 green, 1 red.
- PFE’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ABBV’s TA Score shows that 5 TA indicator(s) are bullish while PFE’s TA Score has 3 bullish TA indicator(s).
- ABBV’s TA Score: 5 bullish, 3 bearish.
- PFE’s TA Score: 3 bullish, 5 bearish.
Price Growth
ABBV (@Pharmaceuticals: Major) experienced а +4.39% price change this week, while PFE (@Pharmaceuticals: Major) price change was -1.36% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -1.06%. For the same industry, the average monthly price growth was -2.23%, and the average quarterly price growth was +2.30%.
Reported Earning Dates
ABBV is expected to report earnings on Jul 24, 2026.
PFE is expected to report earnings on Aug 04, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (-1.06% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| ABBV | PFE | ABBV / PFE | |
| Capitalization | 372B | 144B | 258% |
| EBITDA | 17.6B | 17.2B | 102% |
| Gain YTD | -6.411 | 5.138 | -125% |
| P/E Ratio | 103.13 | 19.34 | 533% |
| Revenue | 61.2B | 63.3B | 97% |
| Total Cash | N/A | 13.1B | - |
| Total Debt | 67.5B | 63.7B | 106% |
ABBV | PFE | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 20 | 74 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 25 Undervalued | 15 Undervalued | |
PROFIT vs RISK RATING 1..100 | 14 | 100 | |
SMR RATING 1..100 | 1 | 76 | |
PRICE GROWTH RATING 1..100 | 56 | 56 | |
P/E GROWTH RATING 1..100 | 22 | 31 | |
SEASONALITY SCORE 1..100 | n/a | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
PFE's Valuation (15) in the Pharmaceuticals Major industry is in the same range as ABBV (25). This means that PFE’s stock grew similarly to ABBV’s over the last 12 months.
ABBV's Profit vs Risk Rating (14) in the Pharmaceuticals Major industry is significantly better than the same rating for PFE (100). This means that ABBV’s stock grew significantly faster than PFE’s over the last 12 months.
ABBV's SMR Rating (1) in the Pharmaceuticals Major industry is significantly better than the same rating for PFE (76). This means that ABBV’s stock grew significantly faster than PFE’s over the last 12 months.
ABBV's Price Growth Rating (56) in the Pharmaceuticals Major industry is in the same range as PFE (56). This means that ABBV’s stock grew similarly to PFE’s over the last 12 months.
ABBV's P/E Growth Rating (22) in the Pharmaceuticals Major industry is in the same range as PFE (31). This means that ABBV’s stock grew similarly to PFE’s over the last 12 months.
| ABBV | PFE | |
|---|---|---|
| RSI ODDS (%) | N/A | N/A |
| Stochastic ODDS (%) | 3 days ago 39% | 3 days ago 59% |
| Momentum ODDS (%) | 3 days ago 65% | 3 days ago 54% |
| MACD ODDS (%) | 3 days ago 73% | N/A |
| TrendWeek ODDS (%) | 3 days ago 59% | 3 days ago 58% |
| TrendMonth ODDS (%) | 3 days ago 61% | 3 days ago 54% |
| Advances ODDS (%) | 4 days ago 57% | 5 days ago 56% |
| Declines ODDS (%) | 10 days ago 48% | 3 days ago 57% |
| BollingerBands ODDS (%) | 3 days ago 63% | 3 days ago 59% |
| Aroon ODDS (%) | 3 days ago 58% | 3 days ago 59% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| NDVG | 33.68 | N/A | N/A |
| Nuveen Dividend Growth ETF | |||
| TBLD | 21.88 | -0.20 | -0.91% |
| Thornburg Income Builder Opportunities Trust | |||
| OPPJ | 60.51 | -0.58 | -0.95% |
| WisdomTree Japan Opportunities ETF | |||
| ACWI | 154.08 | -2.57 | -1.64% |
| iShares MSCI ACWI ETF | |||
| MFEM | 28.16 | -0.84 | -2.89% |
| PIMCO RAFI Dyn Mlt-Fctr Emrg Mkts Eq ETF | |||
ABBV and
Correlation & Price change
A.I.dvisor indicates that over the last year, ABBV has been loosely correlated with PFE. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if ABBV jumps, then PFE could also see price increases.
| Ticker / NAME | Correlation To ABBV | 1D Price Change % | ||
|---|---|---|---|---|
| ABBV | 100% | -0.18% | ||
| PFE - ABBV | 57% Loosely correlated | -1.63% | ||
| BMY - ABBV | 55% Loosely correlated | +0.41% | ||
| AMGN - ABBV | 48% Loosely correlated | -2.22% | ||
| NVS - ABBV | 47% Loosely correlated | -1.13% | ||
| MRK - ABBV | 46% Loosely correlated | -1.79% | ||
More | ||||
PFE and
Correlation & Price change
A.I.dvisor indicates that over the last year, PFE has been loosely correlated with MRK. These tickers have moved in lockstep 66% of the time. This A.I.-generated data suggests there is some statistical probability that if PFE jumps, then MRK could also see price increases.
| Ticker / NAME | Correlation To PFE | 1D Price Change % | ||
|---|---|---|---|---|
| PFE | 100% | -1.63% | ||
| MRK - PFE | 66% Loosely correlated | -1.79% | ||
| BMY - PFE | 62% Loosely correlated | +0.41% | ||
| AMGN - PFE | 54% Loosely correlated | -2.22% | ||
| BIIB - PFE | 54% Loosely correlated | +0.83% | ||
| NVS - PFE | 51% Loosely correlated | -1.13% | ||
More | ||||